Capivasertib (AZD5363) Plus Fulvestrant Versus Placebo Plus Fulvestrant After Relapse or Progression on an Aromatase Inhibitor in Metastatic ER-Positive Breast Cancer (Faktion): a Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
ONCOLOGY RESEARCH AND TREATMENT（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要